These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37357964)
1. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria. Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733 [TBL] [Abstract][Full Text] [Related]
4. Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021. Abbott SL; Etapelong SG; Gidado S; Mawashi KY; Edukugho AA; Hamisu AW; Shehu A; Adedire E; Hassan IA; Waziri NE; Bolu O; Adamu US Pan Afr Med J; 2023; 45(Suppl 2):6. PubMed ID: 38370101 [TBL] [Abstract][Full Text] [Related]
11. Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria. Lorenzetti L; Haydarov R; Namey E; Lawton A; Nam H; Ridwan Hasan M; Monj C; Abeyesekera S; Amina Kabwau M; McIntosh R Vaccine; 2023 Apr; 41 Suppl 1():A128-A135. PubMed ID: 35871107 [TBL] [Abstract][Full Text] [Related]
12. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria. Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307 [TBL] [Abstract][Full Text] [Related]
14. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659 [TBL] [Abstract][Full Text] [Related]
15. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
16. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Mirzoev A; Macklin GR; Zhang Y; Mainou BA; Sadykova U; Olsavszky VS; Huseynov S; Ruziev M; Saidzoda F; Bobokhonova M; Mach O Lancet Glob Health; 2022 Dec; 10(12):e1807-e1814. PubMed ID: 36400086 [TBL] [Abstract][Full Text] [Related]
17. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018. Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908 [TBL] [Abstract][Full Text] [Related]
18. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Thompson KM; Kalkowska DA; Badizadegan K Front Public Health; 2023; 11():1098419. PubMed ID: 37033033 [TBL] [Abstract][Full Text] [Related]
19. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021. Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073 [TBL] [Abstract][Full Text] [Related]
20. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned. Afsar A; Mallya A; Mohammed AAG; Anand S; Diomande VKF; Maufras du Châtellier G; Ather F Vaccine; 2023 Apr; 41 Suppl 1():A79-A84. PubMed ID: 36642630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]